Zevra Therapeutics, Inc. Common Stock (ZVRA) Stock
Key stats
- Market cap
- $705.13M
- Price / Earnings ratio
- 9.1x
- EPS (TTM)
- $1.27
- Volume
- Loading
- 52-week high
- $15.04
- 52-week low
- $8.01
Source: third-party data provider, as of November 13, 2026
Compare with ZVRA
Recent news

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
ZVRA

Zevra Therapeutics Q3 Earnings Call Highlights
Zevra Therapeutics Q3 Earnings Call Highlights
ZVRA

Zevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics Q2 Earnings Call Highlights
ZVRA

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
ZVRA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 60.56
- MACD 12/26/9
- 0.23
- EMA 9 of MACD
- -0.02
- MACD histogram
- 0.25
- SMA 50
- $11.08
- Price above SMA 50
- EMA 50
- $11.00
- Price above EMA 50
- SMA 200
- $10.83
- Price above SMA 200
- EMA 200
- $10.55
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.18 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
ZVRA

Zevra Therapeutics Q3 Earnings Call Highlights
Zevra Therapeutics Q3 Earnings Call Highlights
ZVRA

Zevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics Q2 Earnings Call Highlights
ZVRA

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
ZVRA

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
ZVRA

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
ZVRA

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
ZVRA

ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off?
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off?
ZVRA

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
ZVRA

ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
ZVRA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Zevra Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Neil F. McFarlane | President, CEO & Director | 1973 |
| Mr. Justin A. Renz CPA, MBA | CFO & Treasurer | 1972 |
| Mr. Rahsaan W. Thompson J.D. | Chief Legal Officer, Secretary & Compliance Officer | 1971 |
| Ms. Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications | — |
| Ms. Alison Peters | Chief People Officer | — |
| Dr. Christopher M. Lauderback Ph.D. | Senior Vice President of Manufacturing | 1975 |
| Mr. Joshua M. Schafer M.B.A., M.S. | Chief Commercial Officer | 1972 |
| Dr. Adrian Quartel FFPM, M.D. | Consultant | 1961 |
| Mr. Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality | 1967 |
| Ms. Tanya Hayden | Senior VP & Chief of Staff | 1980 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.56
- MACD 12/26/9
- 0.23
- EMA 9 of MACD
- -0.02
- MACD histogram
- 0.25
- SMA 50
- $11.08
- Price above SMA 50
- EMA 50
- $11.00
- Price above EMA 50
- SMA 200
- $10.83
- Price above SMA 200
- EMA 200
- $10.55
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $26.00
- Average
- $26.00
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +0.7 | -2.7 | -4.4 | -0.4 | -3.9 | +3.5 | -10.4 | -5.1 | +7.0 | +32.1 | ||
| 2024 | -15.2 | +13.1 | -18.1 | -11.2 | +1.1 | +0.4 | +43.9 | +21.4 | -4.9 | +19.0 | +11.1 | -13.8 |
| 2025 | -10.5 | +4.7 | +2.2 | +0.1 | +11.9 | +1.7 | +24.1 | -18.4 | +4.5 | +8.0 | -17.4 | +7.4 |
| 2026 | +7.9 | -4.6 | +2.5 | +8.1 | +15.1 | +24.8 | -31.1 | +16.7 | -9.0 | +1.0 | +17.3 |



